Telix Pharmaceuticals Says FDA Approves New Drug Application for Prostate Cancer Imaging Agent Gozellix

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Telix Pharmaceuticals Says FDA Approves New Drug Application for Prostate Cancer Imaging Agent Gozellix

, MT Newswires - 7:13 AM ET 3/21/2025 default

07:13 AM EDT, 03/21/2025 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) said Friday that the US Food and Drug Administration has approved its new drug application for Gozellix, a PSMA-PET imaging agent for prostate cancer.

Gozellix is indicated for PET scanning of PSMA positive lesions in men having prostate cancer which may have metastasized and are eligible for initial definitive therapy, and those with suspected recurrence of the disease, the company said.

Telix shares were up 3.8% in recent premarket trading.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.